Summary
Previous molecular cytogenetic studies by comparative genomic hybridization (CGH) on primary tumours of human malignant mesothelioma have revealed that loss of genetic material at chromosome 14q is one of the most frequently occurring aberrations. Here we further verify the frequency and pattern of deletions at 14q in mesothelioma. A high-resolution deletion mapping analysis of 23 microsatellite markers was performed on 18 primary mesothelioma tumours. Eight of these had previously been analysed by CGH. Loss of heterozygosity or allelic imbalance with at least one marker was detected in ten of 18 tumours (56%). Partial deletions of varying lengths were more common than loss of all informative markers, which occurred in only one tumour. The highest number of tumours with deletions at a specific marker was detected at 14q11.1–q12 with markers D14S283 (five tumours), D14S972 (seven tumours) and D14S64 (five tumours) and at 14q23–q24 with markers D14S258 (five tumours), D14S77 (five tumours) and D14S284 (six tumours). We conclude from these data that genomic deletions at 14q are more common than previously reported in mesothelioma. Furthermore, confirmation of previous CGH results was obtained in all tumours but one. This tumour showed deletions by allelotyping, but did not show any DNA copy number change at 14q by CGH. Although the number of tumours allelotyped was small and the deletion pattern was complex, 14q11.1–q12 and 14q23–q24 were found to be the most involved regions in deletions. These regions provide a good basis for further molecular analyses and may highlight chromosomal locations of tumour suppressor genes that could be important in the tumorigenesis of malignant mesothelioma.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abujiang, P, Mori, TJ, Takahashi, T, Tanaka, F, Kasyu, I, Hitomi, S & Hiai, H (1998). Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers. Oncogene 17: 3029–3033.
Balsara, BR, Bell, DW, Sonoda, G, De Rienzo, A, du Manoir, S, Jhanwar, SC & Testa, JR (1999). Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1–15 in human malignant mesothelioma. Cancer Res 59: 450–454.
Bandera, CA, Takahashi, H, Behbakht, K, Liu, PC, LiVolsi, VA, Benjamin, I, Morgan, MA, King, SA, Rubin, SC & Boyd, J (1997). Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res 57: 513–515.
Bell, DW, Jhanwar, SC & Testa, JR (1997). Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 57: 4057–4062.
Bianchi, AB, Mitsunaga, S-I, Cheng, JQ, Klein, WM, Jhanwar, SC, Seizinger, B, Kley, N, Klein-Szanto, AJP & Testa, JR (1995). High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesothelioma. Proc Natl Acad Sci USA 92: 10854–10858.
Björkqvist, A-M, Tammilehto, L, Anttila, S, Mattson, K & Knuutila, S (1997). Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 75: 523–527.
Björkqvist, A-M, Tammilehto, L, Nordling, S, Nurminen, M, Anttila, S, Mattson, K & Knuutila, S (1998). Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 77: 260–269.
Browne, K (1986). Mesothelioma registry data. Lancet ii(8499): 167
Chang, WY-H, Cairns, P, Schoenberg, MP, Polascik, TJ & Sidransky, D (1995). Novel suppressor loci on chromosome 14q in primary bladder cancer. Cancer Res 55: 3246–3249.
Cheng, JQ, Jhanwar, SC, Klein, WM, Bell, DW, Lee, W-C, Altomare, DA, Nobori, T, Olopade, OI, Buckler, AJ & Testa, JR (1994). p16 alterations and deletion mapping of 9p21–p22 in malignant mesothelioma. Cancer Res 54: 5547–5551.
Demple, B, Herman, T & Chen, DS (1991). Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: Definition of a family of DNA repair enzymes. Proc Natl Acad Sci USA 88: 11450–11454.
Dib, C, Fauré, S, Fizames, C, Samson, D, Drouot, N, Vignal, A, Millasseau, P, Marc, S, Hazan, J, Seboun, E, Lathrop, M, Gyapay, G, Morissette, J & Weissenbach, J (1996). A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature 380: 152–154.
Fung, H, Kow, YW, Van Houten, B, Taatjes, DJ, Hatahet, Z, Janssen, YMW, Vacek, P, Faux, SP & Mossman, BT (1998). Asbestos increases mammalian AP-endonuclease gene expression, protein levels, and enzyme activity in mesothelial cells. Cancer Res 58: 189–194.
Goodglick, LA & Kane, AB (1990). Cytotoxicity of long and short crocidolite asbestos fibers in vitro and in vivo. Cancer Res 50: 5153–5163.
Hagemeijer, A, Versnel, MA, Van Drunen, E, Moret, M, Bouts, MJ, van der Kwast, TH & Hoogsteden, HC (1990). Cytogenetic analysis of mesothelioma. Cancer Genet Cytogenet 47: 1–28.
Hansen, K & Mossman, BT (1987). Generation of superoxide from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res 47: 1681–1686.
Harrison, L, Ascione, G, Menninger, JC, Ward, DC & Demple, B (1992). Human apurinic endonuclease gene (APE): structure and genomic mapping (chromosome 14q11.2–12). Hum Molec Genet 1: 677–680.
Herbers, J, Schullerus, D, Muller, H, Kenck, C, Chudek, J, Weimer, J, Bugert, P & Kovacs, G (1997). Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas. Genes Chromosomes Cancer 19: 29–35.
Kallioniemi, O-P, Kallioniemi, A, Piper, J, Isola, J, Waldman, FM, Gray, JW & Pinkel, D (1994). Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10: 231–243.
Karjalainen, A, Pukkala, E, Mattson, K, Tammilehto, L & Vainio, H (1997). Trends in mesothelioma incidence and occupational mesotheliomas in Finland in 1960–1995. Scand J Work Environ Health 23: 266–270.
Kivipensas, P, Björkqvist, A-M, Karhu, R, Pelin, K, Linnainmaa, K, Tammilehto, L, Mattson, K, Kallioniemi, O-P & Knuutila, S (1996). Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 89: 7–13.
Lee, W-C, Balsara, B, Liu, Z, Jhanwar, SC & Testa, JR (1996). Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res 56: 4297–4301.
Lu, YY, Jhanwar, SC, Cheng, JQ & Testa, JR (1994). Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer 9: 76–80.
Miller, SA, Dykes, DD & Polesky, HF (1988). A simple salting out procedure for extracting DNAs from human nucleated cells. Nucleic Acids Res 16: 1215
Schwerdtle, RF, Winterpacht, A, Störkel, S, Brenner, W, Hohenfellner, R, Zabel, B, Huber, C & Decker, H-J (1997). Loss of heterozygosity studies and deletion mapping identify two putative chromosome 14q tumor suppressor loci in renal oncocytomas. Cancer Res 57: 5009–5012.
Sekido, Y, Pass, HI, Bader, S, Mew, DJY, Christman, MF, Gazdar, AF & Minna, JD (1995). Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55: 1227–1231.
Simon, M, von Deimling, A, Larson, JJ, Wellenreuther, R, Kaskel, P, Waha, A, Warnick, RE, Tew, JM Jr & Menon, AG (1995). Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: A genetic model of meningioma progression. Cancer Res 55: 4696–4701.
Taguchi, T, Jhanwar, SC, Siegfried, JM, Keller, SM & Testa, JR (1993). Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53: 4349–4355.
Tiainen, M, Tammilehto, L, Rautonen, J, Tuomi, T, Mattson, K & Knuutila, S (1989). Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer 60: 618–626.
Wagner, JC, Sleggs, CA & Marchand, P (1960). Diffuse pleural mesotheliomas and asbestos exposure in the Northwestern Cape Province. Br J Ind Med 17: 260–271.
Yates, DH, Corrin, B, Stidolph, PN & Browne, K (1997). Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 52: 507–512.
Zeiger, MA, Gnarra, JR, Zbar, B, Linehan, WM & Pass, HI (1994). Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes Cancer 11: 15–20.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Björkqvist, AM., Wolf, M., Nordling, S. et al. Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer 81, 1111–1115 (1999). https://doi.org/10.1038/sj.bjc.6690816
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690816
Keywords
This article is cited by
-
DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma
Journal of Experimental & Clinical Cancer Research (2019)
-
DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma
Oncogene (2018)
-
Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines
BMC Genomics (2007)
-
Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma
Oncogene (2001)